These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16131447)

  • 1. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
    García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
    Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
    Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
    Méndez M; Salut A; García-Girón C; Navalon M; Diz P; García López MJ; España P; de la Torre A; Martínez del Prado P; Duarte I; Pujol E; Arizcun A; Cruz JJ
    Clin Colorectal Cancer; 2003 Nov; 3(3):174-9. PubMed ID: 14706177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
    Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
    Antón A; Aranda E; Carrato A; Marcuello E; Massutti B; Cervantes A; Abad A; Sastre J; Fenández-Martos C; Gallén M; Díaz-Rubio E; Huarte L; Balcells M;
    Methods Find Exp Clin Pharmacol; 2003 Oct; 25(8):639-43. PubMed ID: 14671682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
    Rosati G; Cordio S
    Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K; Man S; Mermershtain W; Cohen Y
    J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
    Kalofonos HP; Skarlos D; Bafaloukos D; Papakostas P; Bamias A; Janinis J; Timotheadou E; Kouvatseas G; Stavropoulos M; Economopulos T; Fountzilas G
    Cancer Invest; 2003; 21(6):855-62. PubMed ID: 14735689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
    Aparicio J; Vicent JM; Maestu I; Garcerá S; Busquier I; Bosch C; Llorca C; Díaz R; Fernández-Martos C; Galán A
    Ann Oncol; 2003 Jul; 14(7):1121-5. PubMed ID: 12853356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
    Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A
    Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.
    Fírvida JL; Irigoyen A; Vázquez-Estévez S; Díz P; Constenla M; Casal-Rubio J; Valladares-Ayerbes M; Castellanos J; Rodríguez R; Balcells M
    Cancer; 2001 Feb; 91(4):704-11. PubMed ID: 11241237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.